| Liver Diseases |
NCT01821794: Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B |
|
|
| Active, not recruiting | 3 | 26 | US | Peginterferon and Tenofovir | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Hepatitis B e Antigen Negative, Chronic Hepatitis B e Antigen Positive | 03/13 | 12/17 | | |
NCT01281423: Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection |
|
|
| Active, not recruiting | 2 | 274 | US, Canada, RoW | Placebo, ANA598, Ribavirin, Pegylated Interferon | Hoffmann-La Roche | Hepatitis C | 11/12 | 05/13 | | |
|
|
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients |
|
|
| Recruiting | 2 | 148 | RoW | JKB-122, Placebo | Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd | Chronic Hepatitis C | 08/16 | | | |
NCT02031133: Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C |
|
|
| Active, not recruiting | 2 | 10 | US | Miravirsen | Santaris Pharma A/S | Hepatitis C | 01/17 | 01/17 | | |
NCT00096811: Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program |
|
|
| No Longer Available | N/A | | RoW | Entecavir, Baraclude | Bristol-Myers Squibb | Hepatitis B, Chronic Disease | 08/08 | 08/08 | | |
NCT00263978: Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver |
|
|
| No Longer Available | N/A | | US | Defibrotide | Emory University | Liver Diseases | 06/09 | 06/09 | | |
NCT02011932: Prospective Observational Study of Disease Progression in Chronic Hepatitis C |
|
|
| Active, not recruiting | N/A | 133 | RoW | | Beijing YouAn Hospital | Hepatitis C, Chronic, Disease Progression, Liver Cirrhosis | 06/11 | 07/30 | | |
| No Longer Available | N/A | | US | Buphenyl | University of Pittsburgh | Byler Disease | | | | |
NCT00832273: Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery |
|
|
| No Longer Available | N/A | | US | ELAD® | Vital Therapies, Inc. | Liver Failure | | | | |
NCT01949766: Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease |
|
|
| No Longer Available | N/A | | US | Glycerol phenylbutyrate, RAVICTI | University of Pittsburgh | Byler Disease | | | | |
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
|
|
| No Longer Available | N/A | | US | Melphalan, Percutaneous Hepatic Perfusion | Delcath Systems Inc. | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | | | | |
NCT02082691: Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma |
|
|
| No Longer Available | N/A | | US | G-202 | Devalingam Mahalingam, GenSpera, Inc. | Hepatocellular Carcinoma | | | | |
NCT00589030: Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
|
|
| No Longer Available | N/A | | US | brachytherapy, yttrium Y 90 glass microspheres | City of Hope Medical Center | Liver Cancer | 09/14 | 09/14 | | |
| No Longer Available | N/A | | Europe, RoW | Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin | Janssen-Cilag International NV | Hepatitis C | | | | |
|
|
|
|
|
|
|
|
|
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | Europe | Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
|
|
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | US | Daclatasvir (BMS-790052), Sofosbuvir | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
| Active, not recruiting | N/A | 280 | Europe | Open liver resection, Open liver resection using standard technique:, Ligasure, CUSA, Thunderbeat, Autosonix, SonoSurg, Ultrasound, Laparoscopic liver resection, Laparoscopic liver resection using standardized technique:, Laparoscopic ultrasound | Oslo University Hospital, Helse Sor-Ost | Secondary Malignant Neoplasm of Liver, Colorectal Neoplasms | 04/16 | 12/25 | | |
| Recruiting | N/A | 200 | Europe | | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Liver Cirrhosis | 12/16 | 12/26 | | |
NCT00143546: Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver |
|
|
| No Longer Available | N/A | | US | Defibrotide, Veno-occlusive disease, VOD, Hepatic veno-occlusive disease. | St. Jude Children's Research Hospital | Hepatic Veno-occlusive Disease | | | | |
NCT00701168: Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer |
|
|
| No Longer Available | N/A | | US | yttrium Y 90 microspheres (Therasphere®) | Leo W. Jenkins Cancer Center | Carcinoma, Hepatocellular, Neoplasm Metastasis | | | | |
NCT01306071: Observational Study of Persons With Hepatitis B Virus Infection in North America |
|
|
| Recruiting | N/A | 200 | US | | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative | | | | |
NCT02131441: Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection |
|
|
| Recruiting | N/A | 2 | RoW | laparoscopic hepatectomy, open liver resection | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Laparoscopic Hepatectomy, Hepatocellular Carcinoma | 08/18 | 08/23 | | |
NCT02094222: Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease |
|
|
| No Longer Available | N/A | | NA | RAVICTI, glycerol phenylbutyrate | Robert Squires, Jr. | Byler Disease | | | | |
| No Longer Available | N/A | | US | Omegaven | St. Luke's Health System, Boise, Idaho | Parenteral Nutrition Associated Liver Disease | | | | |
| Active, not recruiting | N/A | 440 | US | iodinated contrast dye, iodinated radiographic dye, motexafin gadolinium, Xcytrin, Eovist-enhanced MRI | American College of Radiology Imaging Network, National Cancer Institute (NCI) | Liver Cancer | 12/23 | 12/23 | | |
NCT00575133: Prospective Cohort Study in Patients With NAFLD |
|
|
| Recruiting | N/A | 150 | Europe | | University of Zurich | Non-alcoholic Fatty Liver Disease | | 11/27 | | |
| Recruiting | N/A | 2000 | Europe | Fibrosis Biomarkers, AST:ALT ratio, APRI, BARD score, ELF Score, FIB4, NAFLD Fibrosis Score,Transient Elastography | University of Nottingham | Chronic Liver Disease, Alcohol Use Disorder, Type 2 Diabetes, Persistently Elevated ALT, Obesity | 05/33 | 05/33 | | |
